Originally developed by Metabolic Pharmaceuticals in Australia during the 1990s, this synthetic peptide was designed to harness growth hormones fat-mobilizing properties while avoiding the metabolic complications associated with full-length GH therapy
Selenophosphate synthetase 2 is the selenoenzyme that catalyzes the ATP-dependent synthesis of selenophosphate from hydrogen selenide ( Figure 4 ) (5)
Researchers monitored food intake, meal size, cravings, body weight, digestive symptoms, hydration, and overall treatment tolerance throughout the first month
Watanabe T, Oku K, Amengual O, Hisada R, Ohmura K, Nakagawa I, Shida H, Bohgaki T, Horita T, Yasuda S (2018) Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies